Debate: The taxane of choice for managing NSCLC is nab-paclitaxel - Agree

Description: With the advancements in the treatment of NSCLC, several thought-provoking issues challenge the thoracic oncologists' perspectives in the optimal management of their patients with lung cancers. The best combination of agents, timing and duration of therapies, patient selection, and appropriate clinical utilization of biomarkers are being considered. The Great Debates and Updates in Thoracic Malignancies 2013 meeting chaired by Dr. Ramaswamy Govindan provides expert-led updates, debates, and discussions of emerging research findings in the field of thoracic malignancies, with the goal of bringing clinicians closer to consensus on these important controversies.